Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose versus standard-dose efavirenz in treatment-naive HIV-1 infection
2009-013795-44Phase 3Completed
- Sponsor
- The Kirby Institute
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of efavirenz in Human immunodeficiency virus infection type 1 (2 arms), sponsored by The Kirby Institute. Primary endpoint: Primary efficacy endpoint. Started Apr 2010; status: completed.
02
Drugs
efavirenz
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2009-013795-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013795-44.